Want to see HK:6872 full AI Analyst Report?
TenNor Therapeutics Suzhou Ltd. Class H (6872) AI Stock Analysis
TenNor Therapeutics Suzhou Ltd. Class H
(HKEX:6872)
The score is primarily constrained by the company's pre-revenue status, recurring losses, and substantial cash burn. Weak technical momentum and the negative P/E ratio add further risk, although the improved balance sheet, reduced debt, and oversold technical readings provide limited mitigating factors.
TenNor Therapeutics Suzhou Ltd. Class H (6872) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.67B
- Dividend Yield
- ―
- Average Volume (3M)
- 103.58K
- Price to Earnings (P/E)
- -20.1
- Beta (1Y)
- -0.20
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 56
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TenNor Therapeutics Suzhou Ltd. Class H Business Overview & Revenue Model
Company Description
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizol...
How the Company Makes Money
null
TenNor Therapeutics Suzhou Ltd. Class H Financial Statement Overview
Summary
Pre-revenue operations, substantial losses, and persistent negative operating cash flow indicate high financial risk. The improved positive equity position and declining debt provide some support, but ongoing capital consumption remains significant.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -430.11K | 0 | 0 | 0 |
| EBITDA | -54.41M | -150.18M | -141.35M | -186.61M |
| Net Income | -75.63M | -153.24M | -145.93M | -191.84M |
Balance Sheet | ||||
| Total Assets | 227.04M | 227.04M | 132.89M | 96.05M |
| Cash, Cash Equivalents and Short-Term Investments | 183.76M | 183.76M | 97.82M | 58.11M |
| Total Debt | 28.65M | 28.65M | 53.02M | 59.42M |
| Total Liabilities | 73.18M | 73.18M | 1.03B | 854.96M |
| Stockholders Equity | 153.86M | 153.86M | -898.05M | -758.91M |
Cash Flow | ||||
| Free Cash Flow | -33.21M | -87.65M | -48.80M | -98.63M |
| Operating Cash Flow | -33.14M | -87.19M | -48.60M | -98.12M |
| Investing Cash Flow | -32.47M | 2.50M | -185.00K | 70.38M |
| Financing Cash Flow | 75.31M | 170.63M | 88.50M | 4.73M |
TenNor Therapeutics Suzhou Ltd. Class H Peers Comparison
Overall Rating
HK:231569Neutral
HK:996965Neutral
HK:685550.1Neutral
HK:968846Neutral- HK:687240Underperform
HK:249339Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2315 | 69Neutral | HKD 17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% |
| HK:9969 | 65Neutral | HKD 16.81B | 12.42 | 17.47% | ― | 146.27% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6855 | 50Neutral | HKD 10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
| HK:6872 | 40Underperform | HKD 3.67B | -20.12 | 41.18% | ― | ― | ― |
| HK:2493 | 39Underperform | HKD 13.86B | -6.55 | -179.83% | ― | 385.38% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6872 | TenNor Therapeutics Suzhou Ltd. Class H | 70.20 | -140.80 | -66.73% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:9969 | InnoCare Pharma Ltd. | 11.25 | -3.37 | -23.05% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 38.30 | 9.06 | 30.98% | |
| HK:6855 | Ascentage Pharma Group International | 27.20 | -40.70 | -59.94% | |
| HK:2493 | Mabwell (Shanghai) Bioscience Co., Ltd. Class H | 18.23 | -9.57 | -34.42% |
TenNor Therapeutics Suzhou Ltd. Class H Corporate Events
TenNor Prioritizes Rifaquizinone for Prosthetic Joint Infection Market
TenNor Therapeutics has designated prosthetic joint infection as the priority indication for its lead drug candidate rifaquizinone, focusing on intra-articular injection as an alternative to surgery for this high-burden complication of joint replacem...
TenNor Therapeutics launches RMB50 million H-share buyback to signal confidence in valuation
TenNor Therapeutics (Suzhou) Limited has received shareholder approval at its second extraordinary general meeting in 2026 to grant the board a general mandate to repurchase up to 5,232,892 H shares, representing no more than 10% of its issued H shar...
TenNor Therapeutics Wins Strong Shareholder Backing for Incentive Plan, Buyback Mandate and Charter Changes
TenNor Therapeutics (Suzhou) Limited secured shareholder approval at its second extraordinary general meeting of 2026, held in Suzhou, for all resolutions proposed by the board, with participation representing about 58% of the company’s H share...
TenNor Advances First-in-Class PJI Antibiotic as Phase IIb Trial Reaches First-Patient Milestone
TenNor Therapeutics has enrolled the first patient in a multi-center Phase IIb clinical trial of its novel antibiotic rifaquizinone (TNP-2092), administered via intra-articular injection for prosthetic joint infection following knee arthroplasty. The...
TenNor Therapeutics Calls 2026 Extraordinary Meeting to Revamp Incentives and Governance
TenNor Therapeutics (Suzhou) Limited has called its second extraordinary general meeting of 2026 for October 23 in Suzhou, inviting H shareholders to participate via poll voting while setting out detailed arrangements on proxy appointments and share...
TenNor Therapeutics Launches 2026 H Share Incentive Plan and Adjusts Articles
TenNor Therapeutics has approved the formulation of a 2026 H share award scheme to create a long‑term incentive plan using existing H shares, aiming to attract and retain key employees, strengthen cohesion and innovation, and better align staff...
TenNor Therapeutics Advances First-in-Class Prosthetic Joint Infection Drug After Positive Phase IIa Data
TenNor Therapeutics (Suzhou) Limited is a PRC-based biopharmaceutical company developing innovative anti-infective drugs for implant-related complications, led by its candidate rifaquizinone (TNP-2092) for prosthetic joint infection. The company seek...
TenNor Therapeutics Narrows Loss and Advances Anti-Infective and CNS Pipeline
TenNor Therapeutics reported interim results for the six months to 30 June 2026 showing a narrowed loss of RMB64.2 million despite higher research and administrative expenses, supported by a sharp increase in cash and cash equivalents to RMB714.7 mil...
TenNor Therapeutics Sets Board Meeting to Review Interim Results and Possible Dividend
TenNor Therapeutics (Suzhou) Limited has scheduled a board meeting for August 26, 2026 to review and approve its interim results for the six months ended June 30, 2026. The board will also consider the potential declaration of an interim dividend, a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026